Producer
Sun Pharmaceutical Industries
World's fourth-largest specialty generic pharma company and India's largest by market cap; major global supplier of psychiatric generics including antidepressants and antipsychotics
1
Inputs supplied
1
Goods downstream
1
Facilities
0
Stories
What they make
1 input Sun Pharmaceutical Industries supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Sun Pharmaceutical Industries makes — pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
US Generics (Largest Segment)
33%India Formulations (Domestic Branded)
27%Specialty Branded (Taro + Innovation)
20%Rest of World + Emerging Markets
15%APIs
5%
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Origin2023
Dilip Shanghvi founded Sun Pharmaceutical Industries in 1983 in Vapi, Gujarat with Rs 10,000 (approximately $200 USD at 1983 exchange rates) and a portfolio of 5 psychiatry drugs. Shanghvi chose psychiatry because branded psychiatric drugs were extremely expensive in India, the chronically ill patient population was enormous and undertreated, and there were few domestic generic competitors. The business premise: make Indian psychiatry affordable. Sun expanded from 5 to 500+ products through aggressive acquisition of small Indian pharma companies throughout the 1990s, then went global with the $4 billion acquisition of Ranbaxy Laboratories in 2015 — India's largest pharma acquisition. Shanghvi became India's richest individual at multiple points due to Sun Pharma's market capitalization. The company founded to treat schizophrenia patients who could not afford branded drugs in Vapi is now India's largest pharmaceutical company by market cap, supplying generic drugs from antipsychotics to specialty biologics in over 100 countries.
Sun Pharmaceutical Industries ↗Did you know2023
Sun Pharma is publicly known as India's largest generic drug company, but through its 2012 acquisition of Taro Pharmaceutical they control a significant share of US generic topical dermatology — a completely different supply chain than oral tablets. Generic tretinoin cream (acne treatment), generic clobetasol propionate (severe eczema, psoriasis), and generic halobetasol are standard first-line dermatology treatments prescribed for tens of millions of US patients annually. Sun/Taro is among the largest US suppliers of these generic topicals. Simultaneously, Sun Pharma's CEQUA product (cyclosporine A ophthalmic nanomicellar solution) competes in the dry eye market alongside Allergan's Restasis and Novartis's Xiidra. A single Indian pharmaceutical conglomerate is simultaneously the largest US generic antipsychotic supplier, a major US generic topical dermatology supplier, and a branded dry eye drug manufacturer — three disconnected therapeutic areas that share only an Indian manufacturing and quality compliance risk.
Sun Pharmaceutical Industries ↗